Advanced

Effects of Argon Laser Trabeculoplasty in the Early Manifest Glaucoma Trial.

Heijl, Anders LU ; Peters, Dorothea LU ; Leske, M Christina and Bengtsson, Boel LU (2011) In American Journal of Ophthalmology 152(5). p.842-848
Abstract
PURPOSE:

To analyze reduction of intraocular pressure (IOP) by argon laser trabeculoplasty (ALT) in the Early Manifest Glaucoma Trial and factors influencing the effect of such treatment.



DESIGN:

Cohort study based on 127 patients from the treatment group of the Early Manifest Glaucoma Trial, a randomized clinical trial.



METHODS:

Patients randomized to the treatment arm of the Early Manifest Glaucoma Trial received a standard treatment protocol (topical betaxolol hydrochloride followed by 360-degree ALT) and then were followed up prospectively at 3-month intervals for up to 8 years. One eye per patient was included in the analyses. We investigated the relationship between IOP... (More)
PURPOSE:

To analyze reduction of intraocular pressure (IOP) by argon laser trabeculoplasty (ALT) in the Early Manifest Glaucoma Trial and factors influencing the effect of such treatment.



DESIGN:

Cohort study based on 127 patients from the treatment group of the Early Manifest Glaucoma Trial, a randomized clinical trial.



METHODS:

Patients randomized to the treatment arm of the Early Manifest Glaucoma Trial received a standard treatment protocol (topical betaxolol hydrochloride followed by 360-degree ALT) and then were followed up prospectively at 3-month intervals for up to 8 years. One eye per patient was included in the analyses. We investigated the relationship between IOP before ALT and subsequent IOP reduction and other factors that might have influenced the effect of ALT, including stage of the disease, trabecular pigmentation, presence of exfoliation syndrome, and treating surgeon.



RESULTS:

The mean ± standard deviation IOP before ALT and after betaxolol treatment was 18.1 ± 3.9 mm Hg, and the mean ± standard deviation short-term IOP reduction 3 months after ALT was 2.8 ± 3.9 mm Hg (12.6 ± 20.5%). The IOP before ALT strongly affected IOP reduction (P < .001); each 3-mm Hg higher IOP before ALT value was associated with an additional mean IOP reduction of approximately 2 mm Hg. The treating surgeons also had a significant impact on IOP reduction (P = 0.001), with mean values ranging from 5.8 to -1.3 mm Hg.



CONCLUSIONS:

In this cohort, which included many patients with low IOP levels, IOP before ALT markedly influenced the IOP reduction induced by ALT, seen as a much larger decrease in eyes with higher IOP before ALT. The treating surgeon also had a significant impact on ALT outcome. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
American Journal of Ophthalmology
volume
152
issue
5
pages
842 - 848
publisher
Elsevier
external identifiers
  • wos:000296413100021
  • pmid:21843876
  • scopus:80055016480
ISSN
1879-1891
DOI
10.1016/j.ajo.2011.04.036
language
English
LU publication?
yes
id
0465c23d-4769-40c8-9e29-2c6536288815 (old id 2151053)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21843876?dopt=Abstract
date added to LUP
2011-09-04 22:08:53
date last changed
2017-07-23 04:14:13
@article{0465c23d-4769-40c8-9e29-2c6536288815,
  abstract     = {PURPOSE:<br/><br>
To analyze reduction of intraocular pressure (IOP) by argon laser trabeculoplasty (ALT) in the Early Manifest Glaucoma Trial and factors influencing the effect of such treatment.<br/><br>
<br/><br>
DESIGN:<br/><br>
Cohort study based on 127 patients from the treatment group of the Early Manifest Glaucoma Trial, a randomized clinical trial.<br/><br>
<br/><br>
METHODS:<br/><br>
Patients randomized to the treatment arm of the Early Manifest Glaucoma Trial received a standard treatment protocol (topical betaxolol hydrochloride followed by 360-degree ALT) and then were followed up prospectively at 3-month intervals for up to 8 years. One eye per patient was included in the analyses. We investigated the relationship between IOP before ALT and subsequent IOP reduction and other factors that might have influenced the effect of ALT, including stage of the disease, trabecular pigmentation, presence of exfoliation syndrome, and treating surgeon.<br/><br>
<br/><br>
RESULTS:<br/><br>
The mean ± standard deviation IOP before ALT and after betaxolol treatment was 18.1 ± 3.9 mm Hg, and the mean ± standard deviation short-term IOP reduction 3 months after ALT was 2.8 ± 3.9 mm Hg (12.6 ± 20.5%). The IOP before ALT strongly affected IOP reduction (P &lt; .001); each 3-mm Hg higher IOP before ALT value was associated with an additional mean IOP reduction of approximately 2 mm Hg. The treating surgeons also had a significant impact on IOP reduction (P = 0.001), with mean values ranging from 5.8 to -1.3 mm Hg.<br/><br>
<br/><br>
CONCLUSIONS:<br/><br>
In this cohort, which included many patients with low IOP levels, IOP before ALT markedly influenced the IOP reduction induced by ALT, seen as a much larger decrease in eyes with higher IOP before ALT. The treating surgeon also had a significant impact on ALT outcome.},
  author       = {Heijl, Anders and Peters, Dorothea and Leske, M Christina and Bengtsson, Boel},
  issn         = {1879-1891},
  language     = {eng},
  number       = {5},
  pages        = {842--848},
  publisher    = {Elsevier},
  series       = {American Journal of Ophthalmology},
  title        = {Effects of Argon Laser Trabeculoplasty in the Early Manifest Glaucoma Trial.},
  url          = {http://dx.doi.org/10.1016/j.ajo.2011.04.036},
  volume       = {152},
  year         = {2011},
}